PL1951283T3 - Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika - Google Patents
Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnikaInfo
- Publication number
- PL1951283T3 PL1951283T3 PL06812748T PL06812748T PL1951283T3 PL 1951283 T3 PL1951283 T3 PL 1951283T3 PL 06812748 T PL06812748 T PL 06812748T PL 06812748 T PL06812748 T PL 06812748T PL 1951283 T3 PL1951283 T3 PL 1951283T3
- Authority
- PL
- Poland
- Prior art keywords
- ovarian cancer
- treating
- pharmaceutical composition
- glycoproteins
- polypeptides
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000004340 zona pellucida Anatomy 0.000 abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010027462 Metastases to ovary Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73687705P | 2005-11-16 | 2005-11-16 | |
EP05110819 | 2005-11-16 | ||
PCT/NL2006/050289 WO2007058536A1 (en) | 2005-11-16 | 2006-11-16 | Pharmaceutical composition for treating or preventing ovarian cancer |
EP06812748A EP1951283B1 (en) | 2005-11-16 | 2006-11-16 | Pharmaceutical composition for treating or preventing ovarian cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1951283T3 true PL1951283T3 (pl) | 2010-12-31 |
Family
ID=37686152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06812748T PL1951283T3 (pl) | 2005-11-16 | 2006-11-16 | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika |
Country Status (8)
Country | Link |
---|---|
US (1) | US7968514B2 (pl) |
EP (1) | EP1951283B1 (pl) |
CN (1) | CN101365473B (pl) |
AT (1) | ATE473756T1 (pl) |
CA (1) | CA2630175C (pl) |
DE (1) | DE602006015508D1 (pl) |
PL (1) | PL1951283T3 (pl) |
WO (1) | WO2007058536A1 (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2586774C2 (ru) * | 2010-08-27 | 2016-06-10 | Пантархей Байосайенс Б.В. | Иммунотерапевтический способ лечения рака простаты |
US20150110897A1 (en) * | 2011-09-15 | 2015-04-23 | University Of Southern California | Sperm Protein as a Detection Biomarker of Early Stage Ovarian Cancer |
CN104804075A (zh) * | 2014-01-24 | 2015-07-29 | 中南大学 | 变异的人卵透明带蛋白1和突变基因及检测方法和应用 |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
WO2016080830A2 (en) * | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
WO2020048924A1 (en) | 2018-09-03 | 2020-03-12 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
WO2023066923A1 (en) | 2021-10-19 | 2023-04-27 | Rahman Nafis | Male contraception |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641487A (en) * | 1989-06-12 | 1997-06-24 | The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services | Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides |
JPH0799974A (ja) * | 1993-10-05 | 1995-04-18 | Tonen Corp | ヒト卵透明帯−2蛋白質をコードするdna |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
WO1999042581A1 (en) * | 1998-02-19 | 1999-08-26 | Eastern Virginia Medical School | RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3) |
US6455041B1 (en) * | 1998-11-17 | 2002-09-24 | Bonita S. Dunbar | Immunogenic epitopes of the human zona pellucida protein (ZP1) |
CA2378472A1 (en) * | 1999-07-01 | 2001-01-11 | The University Of Georgia Research Foundation, Inc. | Method and composition for affecting reproductive systems |
US6455941B1 (en) * | 2001-01-03 | 2002-09-24 | Advanced Semiconductor Engineering, Inc. | Chip scale package |
BRPI0414446A (pt) | 2003-09-18 | 2006-11-14 | Genmab As | métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide |
-
2006
- 2006-11-16 WO PCT/NL2006/050289 patent/WO2007058536A1/en active Application Filing
- 2006-11-16 DE DE602006015508T patent/DE602006015508D1/de active Active
- 2006-11-16 AT AT06812748T patent/ATE473756T1/de not_active IP Right Cessation
- 2006-11-16 CA CA2630175A patent/CA2630175C/en active Active
- 2006-11-16 US US12/093,908 patent/US7968514B2/en not_active Expired - Fee Related
- 2006-11-16 EP EP06812748A patent/EP1951283B1/en active Active
- 2006-11-16 PL PL06812748T patent/PL1951283T3/pl unknown
- 2006-11-16 CN CN2006800511848A patent/CN101365473B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
EP1951283B1 (en) | 2010-07-14 |
CA2630175C (en) | 2018-10-23 |
EP1951283A1 (en) | 2008-08-06 |
US20090060931A1 (en) | 2009-03-05 |
WO2007058536A1 (en) | 2007-05-24 |
CN101365473B (zh) | 2013-04-03 |
CN101365473A (zh) | 2009-02-11 |
ATE473756T1 (de) | 2010-07-15 |
DE602006015508D1 (de) | 2010-08-26 |
CA2630175A1 (en) | 2007-05-24 |
US7968514B2 (en) | 2011-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
PL1951283T3 (pl) | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika | |
MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
WO2006081826A3 (en) | Survivin peptide vaccine | |
MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
MX2020010701A (es) | Péptidos antigénicos para la prevención y el tratamiento del cáncer. | |
NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
HUP0402656A2 (hu) | Sejtterápiás eljárás tumorok kezelésére | |
WO2006023598A3 (en) | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer | |
SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
MX337756B (es) | Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. | |
PH12021551372A1 (en) | Human alpha-galactosidase variants | |
PT1290160E (pt) | Polipeptideos pellino humanos | |
WO2012026820A3 (en) | Immunotherapeutic method for treating prostate cancer | |
WO2004053092A3 (en) | Human pellino polypeptides | |
MX2019012083A (es) | Nueva vacuna de peptidos contra la pcsk9. | |
WO2016080830A3 (en) | Immunotherapeutic method for treating pancreatic cancer |